Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction

A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to... Am J Cardiovasc Drugs (2016) 16:285–295 DOI 10.1007/s40256-016-0174-3 ORIGINAL RESEARCH ARTICLE A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction 1 2 3 1 4 • • • • • John D. Whalen Glenn Davies Mark Du Mustafa Oguz Lori D. Bash Ipek Ozer-Stillman Published online: 4 June 2016 Springer International Publishing Switzerland 2016 Abstract cardiovascular (CV) outcomes. Additional sources Background The TRA 2P-TIMI 50 trial showed the informed inputs for case fatality, bleeding rates on SC, risk addition of vorapaxar to standard care (SC) antiplatelet of non-CV death, and utilities. therapy reduced the combined risk of death, myocardial Results Over a lifetime horizon, fewer CV events and infarction (MI), and stroke, while exhibiting an increase in more bleeding events occurred in the vorapaxar moderate, but not other bleeding events. (VOR) ? SC arm, relative to the SC-only arm. These Objective Our objective was to estimate the long-term results were ultimately accompanied by an increase in life health benefits and risks of vorapaxar as an add-on to SC expectancy and health benefits associated with add-on treatment http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/a-state-transition-model-for-health-outcomes-associated-with-vorapaxar-XRCcq9Sn4V

References (38)

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-016-0174-3
pmid
27262432
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2016) 16:285–295 DOI 10.1007/s40256-016-0174-3 ORIGINAL RESEARCH ARTICLE A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction 1 2 3 1 4 • • • • • John D. Whalen Glenn Davies Mark Du Mustafa Oguz Lori D. Bash Ipek Ozer-Stillman Published online: 4 June 2016 Springer International Publishing Switzerland 2016 Abstract cardiovascular (CV) outcomes. Additional sources Background The TRA 2P-TIMI 50 trial showed the informed inputs for case fatality, bleeding rates on SC, risk addition of vorapaxar to standard care (SC) antiplatelet of non-CV death, and utilities. therapy reduced the combined risk of death, myocardial Results Over a lifetime horizon, fewer CV events and infarction (MI), and stroke, while exhibiting an increase in more bleeding events occurred in the vorapaxar moderate, but not other bleeding events. (VOR) ? SC arm, relative to the SC-only arm. These Objective Our objective was to estimate the long-term results were ultimately accompanied by an increase in life health benefits and risks of vorapaxar as an add-on to SC expectancy and health benefits associated with add-on treatment

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Jun 4, 2016

There are no references for this article.